Viewing Study NCT02606305


Ignite Creation Date: 2025-12-25 @ 3:33 AM
Ignite Modification Date: 2026-02-23 @ 12:23 PM
Study NCT ID: NCT02606305
Status: COMPLETED
Last Update Posted: 2024-06-14
First Post: 2015-11-06
Is Gene Therapy: True
Has Adverse Events: True

Brief Title: Study of Mirvetuximab Soravtansine in Combination With Bevacizumab, Carboplatin, Pegylated Liposomal Doxorubicin, Pembrolizumab, or Bevacizumab + Carboplatin in Participants With Folate Receptor Alpha (FRα) Positive Advanced Epithelial Ovarian Cancer, Primary Peritoneal, or Fallopian Tube Cancer
Sponsor:
Organization: